Quick Answer
Lyell Immunopharma, Inc. reported Research And Development Expense of $182.95 million for the year ending 2023.
- Lyell Immunopharma, Inc. showed an increase of +14.9% in Research And Development Expense from 2022 to 2023.
- This data is from Lyell Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 28, 2024.
- XBRL data for this metric is available from 2019 to 2023 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $97.15 million | Q3 2020: $24.50 million | Q1 2021: $41.53 million | Q2 2021: $46.45 million | Q3 2021: $31.43 million | Q1 2022: $35.83 million | Q2 2022: $43.72 million | Q3 2022: $41.61 million | Q1 2023: $44.63 million | Q2 2023: $47.47 million | Q3 2023: $43.85 million | Q1 2024: $43.17 million | Q2 2024: $40.26 million | Q3 2024: $39.50 million | Q1 2025: $43.45 million | Q2 2025: $34.86 million | Q3 2025: $28.17 million.
- Over the full 5 years of available data (2019 to 2023), Lyell Immunopharma, Inc.'s Research And Development Expense has grown by 187.7%.
- Historical annual values: Fiscal year 2023: $182.95 million | Fiscal year 2022: $159.19 million | Fiscal year 2021: $138.69 million | Fiscal year 2020: $182.24 million | Fiscal year 2019: $63.60 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: